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Chemotherapeutic treatment for cancer has been successful in prolonging survival butmayalso
lead to the development of second cancers. Two case-control studies presented here suggest,
however, that breast cancer patients who receive chemotherapy are atsignificantly lower riskofa
contralateral breast cancer than those who do not. Approximately 300 incident cases of
contralateral breast cancer and 300 randomly chosen surviving controls with unilateral breast
cancer were identified through the Connecticut Tumor Registry for inclusion in each study. The
initial study was based on review of medical records at eight hospitals and indicated that the
overall association with chemotherapy was modified by body build. The second study obtained
information from in-person interviews, hospital records, and outpatient chemotherapy records
from across the state. The preliminary results ofthis second study confirm the previous findings.
Both cytotoxic and hormonal drugs were associated with a reduction in the risk ofsecond breast
cancers (OR = 0.5, 95 percent CI: 0.3-1.0; OR = 0.5, 95 percent CI: 0.2-1.2, respectively).
Significant interaction with body build was observed for hormonal treatment (ratio ofORs - 5.8,
95 percent CI: 1.0-34.3 for a five-unit change in Quetelet's index), with a nonsignificant but
detrimental effect suggested for overweight women (OR = 2.3, 95 percent CI: 0.4-13.9 for a
Quetelet's score of35).
There are a number ofreasons to study multiple primary cancers. These include the
elucidation of cancer etiology and the assessment of any iatrogenic effects resulting
from therapy given for the initial cancer. Although chemotherapeutic treatment has
helped to prolong survival after cancer diagnosis [1], these agents not only kill tumor
cells but may also be carcinogenic themselves [2]. Thus, longer survival combined with
the carcinogenic potential of chemotherapeutic drugs raises the possibility that such
treatment may be involved in the development ofsecond primaries.
There is relatively little information on the relationship between chemotherapy and
the development ofsecond cancers among women with an initial breast cancer. Curtis
et al. [3] have shown that the alkylating agents given for breast cancer therapy are
associated with an increased risk ofdeveloping acute nonlymphocytic leukemia. Horn
et al. [4] found an elevated but not statistically significant association between such
treatment and thedevelopment ofa contralateral breast cancer. Others, however, have
found chemotherapy given for breast cancer to beassociated with a lowered occurrence
ofsecond breast primaries [5-7]. Breast cancerchemotherapy has been available since
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the early 1960s. The adjuvant chemotherapy in common use today began in the
mid-1970s, and in recent years hormonal therapy has become increasingly common,
particularly for the treatment and prophylactic prevention ofmetastases.
We have conducted two case-control studies that have been designed to look at the
broad issue of the risk factors for second breast primaries developing among breast
cancer patients. Both of these studies have included an assessment of the effects of
therapy. The results presented here focus primarily on the preliminary findings
concerning the effects ofchemotherapy from the second ofthese two studies.
METHODS
Hospital Records Study
The methods used in this study have been described in detail elsewhere [7,8].
Briefly, a case-control study was conducted using hospital records as the sole source of
information. Both cases and controls were identified from the records ofthe Connecti-
cut Tumor Registry (CTR). Cases were women who had been newly diagnosed with a
contralateral breast primary in one of eight Connecticut hospitals between July 1,
1975, and December 31, 1983, and who had been diagnosed with an initial breast
cancer in oneofthe same eight hospitals since 1935. Eligible controls were women who
were at risk ofdeveloping a contralateral cancer, i.e., women who had been diagnosed
with an initial breast cancer in one of the eight hospitals since 1935 but had not
developed a second breast cancer nor had had a prophylactic mastectomy of the
contralateral breast. Both independent carcinoma in situ and invasive lesions were
included in the study. Because of difficulties in the differential diagnosis of second
primary cancers versus metastatic spread of the first cancer in the presence ofdistant
metastases or an ipsilateral chest wall recurrence, women with either of these two
conditions were excluded from the study.
From the records ofthe CTR, 309 women were identified as meeting the eligibility
criteria for cases. Hospital records were obtained for 300 (97.1 percent) of these
women. A random sample of 309 women was chosen as the control group from among
7,830 women identified as meeting the above criteria. Hospital records were obtained
for 289 (93.5 percent) ofthese women. Seven cases and 23 controls were subsequently
excluded from the study as ineligible due to a record ofdistant metastases, ipsilateral
chest wall recurrence, or a prophylactic mastectomy in the hospital record. The
diagnosis of the second primary was a pre-malignant condition not routinely reported
to the Registry in one case and was made on clinical, not histologic, grounds for an
additional two cases. These women were also excluded. Finally, two women selected as
controls were found to have had a contralateral breast cancer that was diagnosed
during the study period but had not yet been reported to the Registry. These two
women were excluded as controls and included in the case group. Thus, 292 cases and
264 controls were included in that study.
InterviewStudy
As in the hospital records study, a case-control approach was used to sample
efficiently from a theoretical cohort that consisted ofwomen with a first breast cancer
whowould have been followed forup to 50 years forthedevelopment ofa second breast
primary. The records of the Connecticut Tumor Registry, which date back to 1935,
again offered a unique opportunity to assemble such a cohort. In this study, eligible
cases were women who were diagnosed with a contralateral breast primary between
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July 1, 1983, and September 30, 1986, and who had been diagnosed with an initial
breast cancer since 1935. Cases were required to be residents of Connecticut at the
time of both diagnoses. Thus, cases are representative ofthat portion ofthe theoretical
cohort whose second breast cancers were recently diagnosed.
The controls in these two studies are representative of the portion of the theoretical
cohort who did not develop a second breast cancer. As with the cases, the first breast
cancer in these women had developed at any time since 1935. Their follow-up was
censored at one of the reference dates during the study period. Seven reference dates
were defined, each being the mid-point of successive six-month segments of the study
period, i.e., April 15, 1984, 1985, and 1986, and October 15, 1983, 1984, 1985, and
1986. Since the cases were expected to develop relatively uniformly over the study
period, an equal number of controls were randomly selected into the study at each
specified reference date from among all women meeting the additional eligibility
criteria outlined below. A control had to be alive as of the reference date, a resident of
Connecticut both at the time ofthe initial cancer diagnosis and the reference date, and,
as of the reference date, never have had a contralateral breast cancer nor a
prophylactic mastectomy of the contralateral breast.
A complete pathology review of all initial and contralateral cancers is being
conducted for this study. Thus, women with ipsilateral chest wall recurrences and
distant metastases are not being excluded a priori. Information on reproductive and
menstrual history, family history, health care practices, medical history, smoking
history, and diet is being collected through interviews with study subjects. Information
on tumor characteristics and treatment is being collected through review of histologic
specimens, hospital records, and outpatient medical records. This paper reports on 305
cases and 273 controls interviewed during the first two years of the study.
Analysis
Crude odds ratios (OR) were estimated and corresponding confidence intervals (CI)
were obtained using Woolfs method [9,101]. Unconditional logistic regression analyses
were performed in order to obtain adjusted odds ratios (aOR) [11,12]. Formal
statistical assessment of interaction was performed under a multiplicative model by
including cross-product terms in hierarchical logistic models [12,13]. Estimates of the
magnitude of effect modification are expressed as the ratio of the odds ratios (ROR),
i.e., for dichotomous factors Xand Y, the odds ratio for the relationship between factor
X and the development of a second cancer for women with factor Y divided by the
corresponding odds ratio for women without factor Y.
RESULTS
Table1 presents the associations between the administration of chemotherapy and
the development of a contralateral cancer as observed in the two studies. Both studies
suggest a significant decrease in second breast primaries among those having received
such treatment (OR = 0.3, 95 percent CI: 0.2-0.7 and OR = 0.6, 95 percent CI:
0.4-0.9, for the hospital records study and the interview study, respectively). It should
be noted that here chemotherapy treatment is used in a broad sense and includes both
cytotoxic and hormonal drug therapy. In addition, only chemotherapy administered
before the second cancer diagnosis for cases or the reference date for controls is
included. The estimates for the interview study are not adjusted for possible confound-
ing effects of other factors, most particularly, stage of disease and time since
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TABLE 1
Chemotherapy and the Risk of a Contralateral Breast Cancer: Hospital Records Study
and Interview Study
Chemotherapy Treatment Cases Controls OR 95% CI
Hospital records study
Yes 11 27 0.3a 0.2-0.7
No 281 237 1.0
Interview study
Yes 49 66 0.6 0.4-0.9
No 256 207 1.0
'Adjusted odds ratio = 0.4, 95 percent CI: 0.2-0.9, adjusted for age at initial diagnosis, nulliparity,
menopausal status, exogenous estrogen exposure, cigarette use, benign breast disease prior to initial
cancer, family history of breast cancer in a first- or second-degree relative, tumor histology, stage of
disease, time elapsed since initial diagnosis, blood/rh type, and radiation treatment
administration. However, the crude and adjusted estimates (adjusted for both stage of
diseaseand time sincediagnosis/administration aswell asother factors) in the hospital
record study are similar, suggesting minimal confounding effects.
The protective effect associated with having received chemotherapy did not change
significantly over time in either study (ROR = 1.1, 95 percent CI: 0.7-1.6, and ROR =
0.8, 95 percent CI: 0.7-1.1 for a two-year differential in time since initial cancer
diagnosis, in the hospital records and interview studies, respectively). Figure 1 presents
the fitted odds ratios and 95 percent confidence bands for the modelled effects of this
interaction based on data from the interview study. About three years after initial
cancer diagnosis, the protective effect becomes statistically significant.
Specific information on the drugs, dosages, and duration of administration is
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TABLE 2
Type of Chemotherapy Administered and the Risk of a Contralateral Breast Cancer:
Interview Study""
Type ofDrug Cases Controls OR 95% CI aOR' 95% CI
Cytotoxic 18 27 0.5 0.3-1.0 0.6 0.3-1.2
Hormonal 9 14 0.5 0.2-1.2 0.7 0.3-1.8
None 256 207 1.0 1.0
'Data on type ofchemotherapy administered available for 47 percent ofsubjects receiving chemotherapy
bFour cases and ten controls received both cytotoxic and hormonal therapy
'Adjusting the effects ofeach type ofdrug for having received the other type
currently available for 47 percent of those subjects, in the interview study, who
reported receiving chemotherapy. Table 2 presents the associations between the two
main types ofchemotherapeutic drugs and the development ofa second breast cancer.
Theprotective effect ofhaving receivedchemotherapy is presentfor bothcytotoxic and
hormonal therapy. The only statistically significant effect, however, is for cytotoxic
therapy when adjustment for having received hormonal therapy is not made (OR =
0.5, 95 percent CI: 0.3-1.0). Table 3 presents the average cumulative dose and the
average dose per administration for each ofthe four drugs in most common use today.
The dosages administered to cases and controls were very similar, and no statistically
significant differences were observed. In addition, the duration oftherapy was similar
for cases and controls, with a mean ofapproximately 11 months for cytotoxic therapy
and 17 months for hormonal therapy.
In the hospital record study, an intriguing interaction between chemotherapy and
Quetelet's index (a measure ofbody build) was observed [7]. This interaction suggests
that, for women of low or normal body weight, having received chemotherapy was
associated with a significant decrease in the risk of a contralateral cancer. For
overweight women, however, a nonsignificant but detrimental effect was seen. In the
interview study, the data were also examined for evidence of this interaction, and
similar effect modification was observed when hormonal therapy and Quetelet's index
based on reported weight at age 25 were considered (ROR = 2.4, 95 percent CI:
1.0-5.9 for a 2.5-unit differential in Quetelet's index) (Fig. 2). No such effect
TABLE 3
Dose of Chemotherapy Administered for Cases and Controls: Interview Study'
Average Dose
Cumulative Dose (mg) per Administration (mg)
Cases Controls Cases Controls
Drug Mean + SD Mean + SD Mean ± SD Mean ± SD
Cytoxan 17,571 ± 6,090 17,159 ± 8,577 113 ± 29b 105 ± 29b
Methotrexate 920 + 437 881 ± 486 41 ± 10' 41 ± 16C
5-Fluorouracil 16,597 + 6,579 14,746 + 6,257 740 ± 98' 732 ± 149'
Tamoxifen 7,260 + 5,238 9,709 + 6,192 19 ± 4b 21 ± 6"
"Data on dose ofchemotherapy administered available for 47 percent ofsubjects receivingchemotherapy
bPer day
cEvery two weeks
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modification was observed for cytotoxic therapy nor for either type of therapy when
Quetelet's index was based on subject's report of usual adult weight. As can be seen,
however, in Table 4, which depicts a stratified analysis for this same interaction
between hormonal therapy andQuetelet's index at age 25, theincreased riskassociated
with a Quetelet's score of 35 or more is the result of three observations, and the
addition of one control receiving hormonal therapy would change the detrimental
effect of2.2 to an effect ofapproximately 1.0.
DISCUSSION
The preliminary results from the interview study presented here confirm the
previous findings of the hospital record study [7]. Chemotherapy administered for
breast cancer appears to be protective against the development of a contralateral
breast cancer. Furthermore, while not fully evaluated yet, this protective effect is
demonstrable for up to ten years after diagnosis and appears to be associated with both
hormonal and cytotoxic therapy. More conclusive evidence is needed regarding the
possible modification ofthis effect by body build.
Previous reports of the effects of chemotherapy on the development of a contralat-
eral breast primary have been limited. With an average of three years of follow-up,
Herring et al. [6] found two contralateral cancers among 797 stage II and III breast
cancer patients receiving cytotoxic therapy but six such cancers among 186 patients
not receiving chemotherapy. Cuzick and Baum [5] reported a significant decrease in
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TABLE 4
Interaction Between Hormonal Therapy and Body Build on the Risk of a Contralateral Breast
Cancer: Interview Study'
Quetelet's Index <35 Quetelet's Index .35
Hormonal
Therapy Cases Controls OR 95% CI Cases Controls OR 95% CI
Yes 7 13 0.4 0.2-1.1 2 1 2.2 0.2-25.8
No 245 199 1.0 22 24 1.0
aData on hormonal therapy available for 47 percent ofsubjects receiving chemotherapy
theoccurrence ofcontralateral breast cancers in the first two years offollow-up among
breast cancer patients receiving tamoxifen in a randomized trial. Theonly report ofan
increase in contralateral breast cancers following chemotherapy comes from a
case-control analysis ofdata from the Connecticut Tumor Registry [4]. This elevation
in risk, however, was not statistically significant. The preliminary results of the
interview study reported here suggest that both cytotoxic and hormonal drug therapy
are associated with a reduction in second breast primaries. The effects for each type of
drug alone are not statistically significant; however, there was low statistical precision
because of the small numbers of subjects currently included in the analysis. The
information of the drugs administered in the hospital records study was limited, since
most chemotherapy is given on an outpatient basis, and the overall number ofsubjects
known to be receiving any type of chemotherapy in that study was small. While the
estimates for particular types of drugs were imprecise (primarily as a result of (a)
missing information on type of drug for 19 percent of subjects and (b) 62 percent of
subjects receiving hormonal therapy also received cytotoxic therapy), the results of
that study also suggested a decrease in second breast primaries for both cytotoxic and
hormonal therapy [7]. The much larger proportion ofsubjects receiving chemotherapy
in the interview study as compared to the hospital records study most probably reflects
the more recent time period of the interview study and the increasing use of
chemotherapy in medical practice.
Unlike most other studies todate, the present two studies, particularly the interview
study, have the advantage ofa much longer period ofobservation after the administra-
tion of chemotherapy. Because of the study design, which relies on an internal
comparison, differences in survival between women who develop second primaries and
women who do not cannot affect the results reported here. Both cases and controls are
survivors oftheir initial disease. In both studies a significant protective effect ofhaving
received chemotherapy was observed. The majority ofthe chemotherapy administered
to patients in these two studies was given in the first year or so after the initial cancer
diagnosis. The protective effect observed for chemotherapy was not strongly affected
by the time elapsing since initial cancer diagnosis, a proxy measure for the time since
administration. In the interview study, however, a larger proportion ofchemotherapy
treatment was given after the first year following diagnosis, since exclusions were not
made for women with chest wall recurrences or distant metastases. Further analyses
will consider more precisely the time since administration. In the interview study, the
protective effect of having received chemotherapy continued for up to ten years after
the initial cancer diagnosis. Conclusions regarding the effects of chemotherapy over
time were limited to the first ten years since very few subjects followed for a longer
period had received such treatment. In the years to come, study ofthe effects ofhaving
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received chemotherapy after ten years of follow-up will be of particular interest since
the latency period between tumor induction and clinical detection has been estimated
to be on the order often years for solid tumors [14]. It may be that what we are seeing
now is the systemic effects of chemotherapy in killing developing tumors. Any
carcinogenic potential of chemotherapy treatment may not yet be observable. In
addition, while the current evidence suggests that an added benefit ofchemotherapy is
the prevention ofsecond primaries among those currently selected by medical practice
to receive such therapy, we would not advocate the administration ofchemotherapy to
a wider group of patients without first conducting controlled clinical trials to evaluate
such practice.
The findings from the hospital records study suggested that the effects of chemo-
therapy were modified by body build, such that receiving chemotherapy was found to
be protective against the development of a contralateral cancer among women of
normal or reduced body weight but was associated with an elevated risk among
overweight women [7]. This finding was considered intriguing since toxins may collect
in adipose tissue and the contralateral breast tissue may be especially susceptible to
chemotherapeutic agents, particularly cytotoxic agents which not only kill tumor cells
but may also becarcinogenic. In that study, it was not possible to evaluate whether this
interaction wasthe resultofa particular typeofdrug. Interestingly, theinterview study
found similar effect modification for hormonal therapy but not for cytotoxic therapy.
The hypothesis that the increase in risk associated with chemotherapy in overweight
women was due to thecollection ofdrugs in adipose tissue seems somewhat less tenable
for the hormonal agents than for the cytotoxic agents. Additional issues suggest that
these associations should be interpreted with caution. The interaction in the hospital
records study was with Quetelet's index based on weight at time of first diagnosis,
usually measured directly rather than reported by the patient. In the interview study,
the interaction with hormonal therapy was statistically significant when Quetelet's
score was based on weight at age 25. When usual adult weight was used, the curve was
relatively flat. This somewhat discrepant finding may be related to misclassification;
however, the manner in which this misclassification enters the picture is unclear. It is
not known whether a self-report of weight at age 25 or a self-report of usual adult
weight would be more precisely recalled and thus be a more accurate reflection oftrue
body build. An alternative explanation would simply be that the finding of an
interaction between one type of therapy and a particular measure of body build was
due to chance. Indeed, false-negative and false-positive findings are common when
examining interaction effects [15]. Finally, the tentative nature of the interaction, as
demonstrated in Table 4, adds tothe need for furthercaution ininterpreting thiseffect.
Once the remaining information ofthe specifics oftreatment is available, we expect to
be able to evaluate this interaction more thoroughly.
REFERENCES
1. Bonadonna G, Valagussa P: Dose-response effect ofadjuvant chemotherapy in breast cancer. N Engl J
Med 304:10-15, 1981
2. Sieber SM, Adamson RH: Discussion: Some comments on the potential carcinogenicity ofthe clinically
useful antitumor agents. Cancer 40(Supplement): 1950-1951, 1977
3. Curtis RE, Hankey BF, Myers MH, et al: Risk of leukemia associated with the first course of cancer
treatment: An analysis ofthe Surveillance, Epidemiology, and End Results program experience. JNCI
72:531-544, 1984
4. Horn PL, Thompson WD, Schwartz SM: Factors associated with the risk of second primary breast
cancer: An analysis ofdata from the Connecticut Tumor Registry. J Chron Dis 40:1003-1011, 1987CHEMOTHERAPEUTIC AGENTS AND SECOND BREAST CANCERS 231
5. Cuzick J, Baum M: Tamoxifen and contralateral breast cancer. Lancet ii(8449):282, 1985
6. Herring MK, Buzdar AU, Smith TL, et al: Second neoplasms after adjuvant chemotherapy foroperable
breast cancer. Am J Clin Oncol 9:269-275, 1986
7. Horn PL, Thompson WD: Riskofcontralateral breast cancer: Associations with histologic, clinical, and
therapeutic factors. Submitted for publication
8. Horn PL, Thompson WD: Riskofcontralateral breastcancer: Associations with factors related toinitial
breast cancer. Am J Epidemiol, in press
9. Schlesselman JJ: Case-Control Studies: Design, Conduct, Analysis. New York, Oxford University
Press, 1982
10. Fleiss JL: Statistical Methods for Rates and Proportions. Second edition. New York, John Wiley &
Sons, 1981
11. Kleinbaum DG, Kupper LL, Morgenstern H: Epidemiologic Research: Principles and Quantitative
Methods. Belmont, CA, Lifetime Learning Publications, 1982
12. Kelsey JL, Thompson WD, Evans AS: Methods in Observational Epidemiology. New York, Oxford
University Press, 1986
13. Walter SD, Holford TR: Additive, multiplicative, and other models for disease risk. Am J Epidemiol
108:341-346, 1978
14. Coleman CN: Secondary neoplasms in patients treated for cancer: etiology and perspective. Radiat Res
92:188-200, 1982
15. Smith PG, Day NE: The design of case-control studies: The influence of confounding and interaction
effects. Int J Epidemiol 13:256-265, 1984